Literature DB >> 11943681

Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus.

Katrin Wedde-Beer1, Chengping Hu, Maria M Rodriguez, Giovanni Piedimonte.   

Abstract

Respiratory syncytial virus (RSV) infection potentiates neurogenic inflammation in rat airways. Because some vascular effects of sensory nerves are mediated by cysteinyl leukotrienes (cysLTs), we studied whether the receptor antagonist montelukast inhibits neurogenic plasma extravasation in RSV-infected rats. Pathogen-free rats were inoculated at 2 wk (weanlings) or 12 wk (adults) of age with RSV or virus-free medium and treated with montelukast or its vehicle starting 1 day before inoculation. Five days postinoculation, we measured the extravasation of Evans blue-labeled albumin in the respiratory tract after stimulation of sensory nerves with capsaicin. Montelukast had no effect in the extrapulmonary airways but abolished albumin extravasation in the intrapulmonary airways of RSV-infected rats, with a larger effect in weanlings than in adults. Increased concentrations of 5-lipoxygenase-encoding mRNA and cysLTs, as well as numerous mast cells, were detected in the lung tissues of RSV-infected weanling rats. These observations suggest that the release of neuropeptides from capsaicin-sensitive sensory nerves and nonneuronal cells in the lungs of RSV-infected young rats increases vascular permeability by promoting the release of leukotrienes from mast cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943681     DOI: 10.1152/ajplung.00323.2001

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  15 in total

1.  Expression of 5-lipoxygenase in specialized epithelial cells of nasopharyngeal-associated lymphoid tissue.

Authors:  Thomas G Brock
Journal:  J Mol Histol       Date:  2006-04-28       Impact factor: 2.611

Review 2.  Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.

Authors:  Paul M Brown; Dana L Schneeberger; Giovanni Piedimonte
Journal:  Paediatr Respir Rev       Date:  2015-05-23       Impact factor: 2.726

Review 3.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 4.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 5.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

6.  Combined effects of chronic nicotine and acute virus exposure on neurotrophin expression in rat lung.

Authors:  Fernando Urrego; Mario Scuri; Alexander Auais; Lida Mohtasham; Giovanni Piedimonte
Journal:  Pediatr Pulmonol       Date:  2009-11

Review 7.  Leukotriene receptor antagonist for prolonged non-specific cough in children.

Authors:  A B Chang; D Winter; J P Acworth
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 8.  Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.

Authors:  Mary K McCarthy; Jason B Weinberg
Journal:  Mediators Inflamm       Date:  2012-05-15       Impact factor: 4.711

9.  Role and relevance of mast cells in fungal infections.

Authors:  R Saluja; M Metz; Marcus Maurer
Journal:  Front Immunol       Date:  2012-06-13       Impact factor: 7.561

Review 10.  How exposures to biologics influence the induction and incidence of asthma.

Authors:  Darryl C Zeldin; Peyton Eggleston; Martin Chapman; Giovanni Piedimonte; Harard Renz; David Peden
Journal:  Environ Health Perspect       Date:  2006-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.